Magle Chemoswed

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organisation (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology

Magle Group positions innovation at the core of its identity, offering CDMO services that support the development and delivery of advanced therapies. The company develops and commercialises technologies grounded in science and validated through clinical evidence. Its proprietary Degradable Starch Microsphere (DSM) technology is already incorporated in multiple approved products, benefiting more than 150,000 patients worldwide. With additional platforms in dextran and amniotic stem cells, Magle Group is expanding into high-impact areas including oncology, wound care, immunotherapy, and regenerative medicine.

The company manages the full development lifecycle in-house, from early research and scale-up to commercial manufacturing and sales. Its integrated capabilities encompass quality assurance, regulatory compliance, logistics, and clinical trials. By maintaining end-to-end control, Magle Group ensures consistently high standards of quality, efficiency, and speed, establishing itself as a reliable and forward-looking partner in the healthcare sector.

Since 2021, Magle Group has been building a scalable direct sales organisation across Europe. The acquisition of PharmaCept provided an established European sales network, while the addition of Amniotics AB expanded the company’s portfolio with advanced amniotic stem cell technologies. The acquisition of PKC further strengthened Magle Group’s capabilities in contract manufacturing and sterile production, enhancing its comprehensive CDMO offering.

ADDRESS 
Agneslundsvägen 27, 212 15 Malmö, Sweden

CONTACT
Aaron Wong, Interim CEO, aaron.wong@maglegroup.com

WEBSITE
Magle Group